Sort   by:  
 Page size 
ProteomicsIP-MS of SMARCC1-bound SWI/SNF complexes in PRT3789-treated Calu-6 and NCI-H1693 cell lines
Immunoprecipitation-mass spectrometry (IP-MS) was performed in Calu-6 (SMARCA4-WT) and NCI-H1693 (SMARCA4-del) cell lines treated with the SMARCA2-selective degrader PRT3789 for 6 or 48 hours. SWI/SNF complexes were immunoprecipitated using an antibody against SMARCC1 and analyzed by LC-MS/MS.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2025-06-12 | MSV000098173 | MassIVE
ProteomicsIP-MS of SMARCC1-bound SWI/SNF complexes in Calu-6 and NCI-H1693 cells treated with a SMARCA2-selective ATPase inhibitor (48 hr)
Immunoprecipitation-mass spectrometry (IP-MS) was performed in Calu-6 (SMARCA4-WT) and NCI-H1693 (SMARCA4-del) cell lines treated for 48 hours with a SMARCA2-selective ATPase inhibitor. SWI/SNF complexes were enriched using SMARCC1 immunoprecipitation, followed by LC-MS/MS analysis.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2025-06-12 | MSV000098172 | MassIVE
ProteomicsNCI-H1693 (SMARCA4-del) PRT3789 Global Proteomics
NCI-H1693 (SMARCA4-del) cell line treated with PRT3789 for 6 hr and 48 hr.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2025-06-12 | MSV000098139 | MassIVE
ProteomicsCalu-6 (SMARCA4-WT) PRT3789 Global Proteomics
Calu-6 (SMARCA4-WT) cell line treated with PRT3789 for 6 hr and 48 hr.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2025-06-11 | MSV000098129 | MassIVE
UnknownSimvastatin in Critically Ill Patients with Covid-19.
Not available
S-EPMC10755839 | biostudies-literature
UnknownEffect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8491132 | biostudies-literature
UnknownEffect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC10326520 | biostudies-literature
UnknownEffect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8941448 | biostudies-literature
UnknownLong-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Not available
S-EPMC9857594 | biostudies-literature
UnknownIntravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.
Not available
S-EPMC10600726 | biostudies-literature
Sort   by:  
 Page size